{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:00:29Z","timestamp":1788184829378,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007232","name":"Radiumhemmets Forskningsfonder","doi-asserted-by":"publisher","award":["214062"],"award-info":[{"award-number":["214062"]}],"id":[{"id":"10.13039\/501100007232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["4-2686\/2022"],"award-info":[{"award-number":["4-2686\/2022"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018713","name":"Center for Innovative Medicine","doi-asserted-by":"publisher","award":["985908"],"award-info":[{"award-number":["985908"]}],"id":[{"id":"10.13039\/501100018713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Oral squamous cell carcinoma (OSCC), while common and with a favorable prognosis in early stages, presents a marked reduction in survival rate upon metastasis to lymph nodes. Early detection of lymph node metastasis via biomarkers could enhance the therapeutic strategy for OSCC. Here, we explored dendritic cells (DCs) and cytotoxic T-cells in tumour-draining lymph nodes (TDLNs) as potential biomarkers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>Dendritic cells and cytotoxic T-cells in 33 lymph nodes were analyzed with multi-parameter flow cytometry in TDLNs, regional non-TDLNs surgically excised from 12 OSCC patients, and compared to 9 lymph nodes from patients with benign conditions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our results displayed a higher proportion of conventional cDC1s with immunosuppressive features in TDLN. Further, high PD-L1 expression on cDC1 in TDLNs was associated with metastasis and\/or recurrent disease risk. Also, elevated levels of memory CD8<jats:sup>+<\/jats:sup>\u00a0T-cells and terminally exhausted PD-1<jats:sup>+<\/jats:sup>TCF-1<jats:sup>\u2212<\/jats:sup>CD8<jats:sup>+<\/jats:sup> T-cells were observed in TDLNs and non-TDLNs compared to healthy lymph nodes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We conclude that TDLNs contain cells that could trigger an anti-tumor adaptive response, as evidenced by activated cDC1s and progenitor-like TCF-1<jats:sup>+<\/jats:sup>\u00a0T-cells. The detection of high PDL1 expression on cDC1s was indicative of TDLN metastasis and an adverse prognosis, proposing that PD-L1 on dendritic cells in TDLN could serve as a predictive biomarker of OSCC patients with a worse prognosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00262-024-03754-x","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T13:02:19Z","timestamp":1719925339000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["High expression of PD-L1 on conventional dendritic cells in tumour-draining lymph nodes is associated with poor prognosis in oral cancer"],"prefix":"10.1007","volume":"73","author":[{"given":"Hjalmarsson","family":"Eric","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Piersiala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilma","family":"Lagebro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Farrajota Neves Da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Petro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Starkhammar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Elliot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rusana","family":"Bark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregori","family":"Margolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Kumlien Geor\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars-Olaf","family":"Cardell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"issue":"9","key":"3754_CR1","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41415-022-5166-x","volume":"233","author":"M Gormley","year":"2022","unstructured":"Gormley M, Creaney G, Schache A, Ingarfield K, Conway DI (2022) Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. Br Dent J 233(9):780\u2013786. https:\/\/doi.org\/10.1038\/s41415-022-5166-x","journal-title":"Br Dent J"},{"issue":"3","key":"3754_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"3754_CR3","unstructured":"https:\/\/seer.cancer.gov\/statistics-network\/explorer\/"},{"issue":"4","key":"3754_CR4","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.trecan.2019.02.007","volume":"5","author":"JD Horton","year":"2019","unstructured":"Horton JD, Knochelmann HM, Day TA, Paulos CM, Neskey DM (2019) Immune evasion by head and neck cancer: foundations for combination therapy. Trends Cancer 5(4):208\u2013232. https:\/\/doi.org\/10.1016\/j.trecan.2019.02.007","journal-title":"Trends Cancer"},{"key":"3754_CR5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG (2021) Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol 16:223\u2013249. https:\/\/doi.org\/10.1146\/annurev-pathol-042020-042741","journal-title":"Annu Rev Pathol"},{"issue":"4","key":"3754_CR6","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson DB, Nebhan CA, Moslehi JJ, Balko JM (2022) Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol 19(4):254\u2013267. https:\/\/doi.org\/10.1038\/s41571-022-00600-w","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"3754_CR7","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","volume":"17","author":"TY Seiwert","year":"2016","unstructured":"Seiwert TY et al (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 17(7):956\u2013965. https:\/\/doi.org\/10.1016\/S1470-2045(16)30066-3","journal-title":"Lancet Oncol"},{"key":"3754_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.101977","volume":"84","author":"N Gavrielatou","year":"2020","unstructured":"Gavrielatou N, Doumas S, Economopoulou P, Foukas PG, Psyrri A (2020) Biomarkers for immunotherapy response in head and neck cancer. Cancer Treat Rev 84:101977. https:\/\/doi.org\/10.1016\/j.ctrv.2020.101977","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"3754_CR9","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s40425-019-0662-5","volume":"7","author":"EEW Cohen","year":"2019","unstructured":"Cohen EEW et al (2019) The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer 7(1):184. https:\/\/doi.org\/10.1186\/s40425-019-0662-5","journal-title":"J Immunother Cancer"},{"key":"3754_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.coph.2015.05.011","volume":"23","author":"J Sunshine","year":"2015","unstructured":"Sunshine J, Taube JM (2015) PD-1\/PD-L1 inhibitors. Curr Opin Pharmacol 23:32\u201338. https:\/\/doi.org\/10.1016\/j.coph.2015.05.011","journal-title":"Curr Opin Pharmacol"},{"issue":"10","key":"3754_CR11","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1001\/jamaoncol.2020.2955","volume":"6","author":"JD Schoenfeld","year":"2020","unstructured":"Schoenfeld JD et al (2020) Neoadjuvant Nivolumab or Nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial. JAMA Oncol 6(10):1563\u20131570. https:\/\/doi.org\/10.1001\/jamaoncol.2020.2955","journal-title":"JAMA Oncol"},{"issue":"19","key":"3754_CR12","doi-asserted-by":"publisher","first-page":"5140","DOI":"10.1158\/1078-0432.CCR-20-1695","volume":"26","author":"R Uppaluri","year":"2020","unstructured":"Uppaluri R et al (2020) Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase II trial. Clin Cancer Res 26(19):5140\u20135152. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1695","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3754_CR13","doi-asserted-by":"publisher","first-page":"7348","DOI":"10.1038\/s41467-021-26472-9","volume":"12","author":"JL Vos","year":"2021","unstructured":"Vos JL et al (2021) Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. Nat Commun 12(1):7348. https:\/\/doi.org\/10.1038\/s41467-021-26472-9","journal-title":"Nat Commun"},{"issue":"7","key":"3754_CR14","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1158\/1078-0432.CCR-21-3351","volume":"28","author":"TM Wise-Draper","year":"2022","unstructured":"Wise-Draper TM et al (2022) Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma. Clin Cancer Res 28(7):1345\u20131352. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3351","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3754_CR15","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","volume":"38","author":"F Dammeijer","year":"2020","unstructured":"Dammeijer F et al (2020) The PD-1\/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes. Cancer Cell 38(5):685\u2013700. https:\/\/doi.org\/10.1016\/j.ccell.2020.09.001","journal-title":"Cancer Cell"},{"issue":"1","key":"3754_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1):1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012","journal-title":"Immunity"},{"issue":"2","key":"3754_CR17","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov H, Orhan A, Christensen JP, Gogenur I (2021) Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. Br J Cancer 124(2):359\u2013367. https:\/\/doi.org\/10.1038\/s41416-020-01048-4","journal-title":"Br J Cancer"},{"issue":"1","key":"3754_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D (2020) Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol 20(1):7\u201324. https:\/\/doi.org\/10.1038\/s41577-019-0210-z","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"3754_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/cyto.a.24269","volume":"99","author":"F Mair","year":"2021","unstructured":"Mair F, Liechti T (2021) Comprehensive phenotyping of human dendritic cells and monocytes. Cytom A 99(3):231\u2013242. https:\/\/doi.org\/10.1002\/cyto.a.24269","journal-title":"Cytom A"},{"issue":"2","key":"3754_CR20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/eji.201546023","volume":"46","author":"MC Chiang","year":"2016","unstructured":"Chiang MC et al (2016) Differential uptake and cross-presentation of soluble and necrotic cell antigen by human DC subsets. Eur J Immunol 46(2):329\u2013339. https:\/\/doi.org\/10.1002\/eji.201546023","journal-title":"Eur J Immunol"},{"issue":"5","key":"3754_CR21","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.immuni.2014.04.016","volume":"40","author":"A Mildner","year":"2014","unstructured":"Mildner A, Jung S (2014) Development and function of dendritic cell subsets. Immunity 40(5):642\u2013656. https:\/\/doi.org\/10.1016\/j.immuni.2014.04.016","journal-title":"Immunity"},{"key":"3754_CR22","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.3389\/fimmu.2017.01764","volume":"8","author":"MP Domogalla","year":"2017","unstructured":"Domogalla MP, Rostan PV, Raker VK, Steinbrink K (2017) Tolerance through education: how tolerogenic dendritic cells shape immunity. Front Immunol 8:1764. https:\/\/doi.org\/10.3389\/fimmu.2017.01764","journal-title":"Front Immunol"},{"issue":"3","key":"3754_CR23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.coi.2007.04.012","volume":"19","author":"ME Keir","year":"2007","unstructured":"Keir ME, Francisco LM, Sharpe AH (2007) PD-1 and its ligands in T-cell immunity. Curr Opin Immunol 19(3):309\u2013314. https:\/\/doi.org\/10.1016\/j.coi.2007.04.012","journal-title":"Curr Opin Immunol"},{"issue":"8","key":"3754_CR24","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.3390\/cancers14081976","volume":"14","author":"Y Saito","year":"2022","unstructured":"Saito Y, Komori S, Kotani T, Murata Y, Matozaki T (2022) The role of type-2 conventional dendritic cells in the regulation of tumor immunity. Cancers (Basel) 14(8):1976. https:\/\/doi.org\/10.3390\/cancers14081976","journal-title":"Cancers (Basel)"},{"key":"3754_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.749190","volume":"12","author":"B Zhou","year":"2021","unstructured":"Zhou B, Lawrence T, Liang Y (2021) The role of plasmacytoid dendritic cells in cancers. Front Immunol 12:749190. https:\/\/doi.org\/10.3389\/fimmu.2021.749190","journal-title":"Front Immunol"},{"issue":"1","key":"3754_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1600-065X.2011.01006.x","volume":"241","author":"TA Ferguson","year":"2011","unstructured":"Ferguson TA, Choi J, Green DR (2011) Armed response: how dying cells influence T-cell functions. Immunol Rev 241(1):77\u201388. https:\/\/doi.org\/10.1111\/j.1600-065X.2011.01006.x","journal-title":"Immunol Rev"},{"issue":"1","key":"3754_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nri3790","volume":"15","author":"LT Nguyen","year":"2015","unstructured":"Nguyen LT, Ohashi PS (2015) Clinical blockade of PD1 and LAG3\u2013potential mechanisms of action. Nat Rev Immunol 15(1):45\u201356. https:\/\/doi.org\/10.1038\/nri3790","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"3754_CR28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41368-022-00160-w","volume":"14","author":"D Wang","year":"2022","unstructured":"Wang D et al (2022) A comprehensive profile of TCF1(+) progenitor and TCF1(-) terminally exhausted PD-1(+)CD8(+) T cells in head and neck squamous cell carcinoma: implications for prognosis and immunotherapy. Int J Oral Sci 14(1):8. https:\/\/doi.org\/10.1038\/s41368-022-00160-w","journal-title":"Int J Oral Sci"},{"issue":"1","key":"3754_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s40425-019-0605-1","volume":"7","author":"KM van Pul","year":"2019","unstructured":"van Pul KM et al (2019) Selectively hampered activation of lymph node-resident dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node. J Immunother Cancer 7(1):133. https:\/\/doi.org\/10.1186\/s40425-019-0605-1","journal-title":"J Immunother Cancer"},{"issue":"1","key":"3754_CR30","doi-asserted-by":"publisher","first-page":"22352","DOI":"10.1038\/s41598-020-79273-3","volume":"10","author":"A Kagedal","year":"2020","unstructured":"Kagedal A et al (2020) Activation of T helper cells in sentinel node predicts poor prognosis in oral squamous cell carcinoma. Sci Rep 10(1):22352. https:\/\/doi.org\/10.1038\/s41598-020-79273-3","journal-title":"Sci Rep"},{"issue":"3","key":"3754_CR31","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/cas.14816","volume":"112","author":"K Piersiala","year":"2021","unstructured":"Piersiala K et al (2021) CD4(+) and CD8(+) T cells in sentinel nodes exhibit distinct pattern of PD-1, CD69, and HLA-DR expression compared to tumor tissue in oral squamous cell carcinoma. Cancer Sci 112(3):1048\u20131059. https:\/\/doi.org\/10.1111\/cas.14816","journal-title":"Cancer Sci"},{"key":"3754_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/v15020451","author":"SK Katirachi","year":"2023","unstructured":"Katirachi SK, Gronlund MP, Jakobsen KK, Gronhoj C, von Buchwald C (2023) The prevalence of HPV in oral cavity squamous cell carcinoma. Viruses. https:\/\/doi.org\/10.3390\/v15020451","journal-title":"Viruses"},{"issue":"31","key":"3754_CR33","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.2174\/1381612826666200213100750","volume":"26","author":"\u00c5 K\u00e5gedal","year":"2020","unstructured":"K\u00e5gedal \u00c5 et al (2020) A novel sentinel lymph node approach in oral squamous cell carcinoma (in eng). Curr Pharm Des 26(31):3834\u20133839. https:\/\/doi.org\/10.2174\/1381612826666200213100750","journal-title":"Curr Pharm Des"},{"issue":"7","key":"3754_CR34","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/cyto.a.22625","volume":"87","author":"S Van Gassen","year":"2015","unstructured":"Van Gassen S et al (2015) FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. Cytom A 87(7):636\u2013645. https:\/\/doi.org\/10.1002\/cyto.a.22625","journal-title":"Cytom A"},{"key":"3754_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav7431","author":"M Mayoux","year":"2020","unstructured":"Mayoux M et al (2020) Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aav7431","journal-title":"Sci Transl Med"},{"issue":"7","key":"3754_CR36","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s43018-020-0075-x","volume":"1","author":"SA Oh","year":"2020","unstructured":"Oh SA et al (2020) PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nat Cancer 1(7):681\u2013691. https:\/\/doi.org\/10.1038\/s43018-020-0075-x","journal-title":"Nat Cancer"},{"issue":"4","key":"3754_CR37","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","volume":"44","author":"H Salmon","year":"2016","unstructured":"Salmon H et al (2016) Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 44(4):924\u2013938. https:\/\/doi.org\/10.1016\/j.immuni.2016.03.012","journal-title":"Immunity"},{"issue":"10","key":"3754_CR38","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.immuni.2021.08.026","volume":"54","author":"JM Schenkel","year":"2021","unstructured":"Schenkel JM et al (2021) Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1(+) CD8(+) T cells in tumor-draining lymph nodes. Immunity 54(10):2338\u20132353. https:\/\/doi.org\/10.1016\/j.immuni.2021.08.026","journal-title":"Immunity"},{"issue":"6","key":"3754_CR39","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1158\/2326-6066.CIR-13-0114-T","volume":"1","author":"C Aspord","year":"2013","unstructured":"Aspord C, Leccia MT, Charles J, Plumas J (2013) Plasmacytoid dendritic cells support melanoma progression by promoting Th2 and regulatory immunity through OX40L and ICOSL. Cancer Immunol Res 1(6):402\u2013415. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0114-T","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"3754_CR40","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1002\/cncr.26511","volume":"118","author":"TO Jensen","year":"2012","unstructured":"Jensen TO et al (2012) Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I\/II melanoma. Cancer 118(9):2476\u20132485. https:\/\/doi.org\/10.1002\/cncr.26511","journal-title":"Cancer"},{"issue":"19","key":"3754_CR41","first-page":"6478","volume":"63","author":"E Hartmann","year":"2003","unstructured":"Hartmann E et al (2003) Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 63(19):6478\u20136487","journal-title":"Cancer Res"},{"key":"3754_CR42","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jneuroim.2018.06.012","volume":"322","author":"D Mitchell","year":"2018","unstructured":"Mitchell D, Chintala S, Dey M (2018) Plasmacytoid dendritic cell in immunity and cancer. J Neuroimmunol 322:63\u201373. https:\/\/doi.org\/10.1016\/j.jneuroim.2018.06.012","journal-title":"J Neuroimmunol"},{"key":"3754_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.733800","volume":"13","author":"YH Gupta","year":"2022","unstructured":"Gupta YH, Khanom A, Acton SE (2022) Control of dendritic cell function within the tumour microenvironment. Front Immunol 13:733800. https:\/\/doi.org\/10.3389\/fimmu.2022.733800","journal-title":"Front Immunol"},{"issue":"1","key":"3754_CR44","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.1038\/s41467-020-18570-x","volume":"11","author":"Q Peng","year":"2020","unstructured":"Peng Q et al (2020) PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat Commun 11(1):4835. https:\/\/doi.org\/10.1038\/s41467-020-18570-x","journal-title":"Nat Commun"},{"issue":"1","key":"3754_CR45","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008026","volume":"12","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zhu T, Shi Q, Zhu G, Zhu S, Hou F (2024) Tumor-draining lymph nodes: opportunities, challenges, and future directions in colorectal cancer immunotherapy. J Immunother Cancer 12(1):e008026. https:\/\/doi.org\/10.1136\/jitc-2023-008026","journal-title":"J Immunother Cancer"},{"issue":"10","key":"3754_CR46","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1007\/s00262-019-02330-y","volume":"68","author":"J Rotman","year":"2019","unstructured":"Rotman J, Koster BD, Jordanova ES, Heeren AM, de Gruijl TD (2019) Unlocking the therapeutic potential of primary tumor-draining lymph nodes. Cancer Immunol Immunother 68(10):1681\u20131688. https:\/\/doi.org\/10.1007\/s00262-019-02330-y","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"3754_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008437","volume":"5","author":"J Desfrancois","year":"2010","unstructured":"Desfrancois J et al (2010) Double positive CD4CD8 alphabeta T cells: a new tumor-reactive population in human melanomas. PLoS ONE 5(1):e8437. https:\/\/doi.org\/10.1371\/journal.pone.0008437","journal-title":"PLoS ONE"},{"issue":"563","key":"3754_CR48","doi-asserted-by":"publisher","first-page":"aay3575","DOI":"10.1126\/scitranslmed.aay3575","volume":"12","author":"DM Francis","year":"2020","unstructured":"Francis DM et al (2020) Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy. Sci Transl Med 12(563):aay3575. https:\/\/doi.org\/10.1126\/scitranslmed.aay3575","journal-title":"Sci Transl Med"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03754-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03754-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03754-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T12:03:47Z","timestamp":1723464227000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03754-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":48,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["3754"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03754-x","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]},"assertion":[{"value":"9 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"165"}}